The XPD Lys751Gln, XPC Ala499Val and XPC Lys939Gln polymorphisms were associated with higher risk for relapse and shorter survival in patients with acute myeloid leukemia that had been placed by pre-treatment cytogenetics into the ‘intermediate’ risk group, where risk of relapse was difficult to evaluate by other methods (50). Here, XPC is linked to acute myeloid leukemia.